Back to Search
Start Over
A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancer.
- Source :
-
Gynecologic Oncology . 2024 Supplement 1, Vol. 190, pS290-S290. 1p. - Publication Year :
- 2024
- Subjects :
- *ANLOTINIB
*CERVICAL cancer
*CLINICAL trials
*METASTASIS
*SAFETY
Subjects
Details
- Language :
- English
- ISSN :
- 00908258
- Volume :
- 190
- Database :
- Academic Search Index
- Journal :
- Gynecologic Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 180154342
- Full Text :
- https://doi.org/10.1016/j.ygyno.2024.07.431